Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
grade D 13.43 3.79% 0.49
OMER closed up 3.79 percent on Friday, January 18, 2019, on 76 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical OMER trend table...

Date Alert Name Type % Chg
Jan 18 Crossed Above 50 DMA Bullish 0.00%
Jan 18 MACD Bullish Centerline Cross Bullish 0.00%
Jan 18 180 Bullish Setup Bullish Swing Setup 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 17 50 DMA Resistance Bearish 3.79%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.79%
Jan 17 Inside Day Range Contraction 3.79%
Jan 17 Upper Bollinger Band Touch Strength 3.79%
Jan 16 Fell Below 50 DMA Bearish 3.95%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.95%

Older signals for OMER ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Is OMER a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.0
52 Week Low 8.36
Average Volume 805,320
200-Day Moving Average 17.6154
50-Day Moving Average 13.0634
20-Day Moving Average 12.1025
10-Day Moving Average 12.679
Average True Range 0.8871
ADX 19.9
+DI 22.2298
-DI 12.9608
Chandelier Exit (Long, 3 ATRs ) 11.6687
Chandelier Exit (Short, 3 ATRs ) 12.9613
Upper Bollinger Band 13.7045
Lower Bollinger Band 10.5005
Percent B (%b) 0.91
BandWidth 26.473869
MACD Line 0.0049
MACD Signal Line -0.2474
MACD Histogram 0.2523
Fundamentals Value
Market Cap 601.7 Million
Num Shares 44.8 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -9.14
Price-to-Sales 11.55
Price-to-Book 0.00
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.15
Resistance 3 (R3) 14.08 13.77 14.03
Resistance 2 (R2) 13.77 13.59 13.81 13.99
Resistance 1 (R1) 13.60 13.47 13.69 13.67 13.95
Pivot Point 13.29 13.29 13.33 13.33 13.29
Support 1 (S1) 13.12 13.11 13.21 13.19 12.91
Support 2 (S2) 12.81 12.99 12.85 12.87
Support 3 (S3) 12.64 12.81 12.83
Support 4 (S4) 12.71